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Abstract
Fecal incontinence is a disabling symptom with medical 
and social implications, including fear, embarrassment, 
isolation and even depression. Most patients live in se-
clusion and have to plan their life around the symptom, 
with secondary impairment of their quality of life. Con-
servative management and biofeedback therapy are 
reported to benefit a good percentage of those affect-
ed. However, surgery must be considered in the non-
responder population. Recently, sacral nerve electro-
stimulation, lately named neuromodulation, has been 
reported to benefit patients with fecal incontinence in 
randomized controlled trials more than placebo stimula-
tion and conservative management, by some unknown 
mechanism. Neuromodulation is a minimally invasive 
procedure with a low rate of adverse events and ap-
parently favorable cost-efficacy profile. This review is 
intended to expand knowledge about this effective in-
tervention among the non-surgically skilled community 
who deals with this disabled group of patients. 
© 2013 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: This review summarizes the evidence for neu-
romodulation of fecal incontinence. Neuromodulation 
is effective for some patients with fecal incontinence of 
different etiology unknown mechanism; when analyzed 
by intent to treat analysis, the median responder rate is 
59%. The most common serious adverse event is infec-
tion at the site of implant which occurs in about 3% of 
patients. Cost of treatment is high relative to conserva-
tive treatment and biofeedback but seems to be cost-
effective when offset by gains in quality-adjusted years. 
Randomized controlled trials comparing neuromodula-
tion with biofeedback therapy in fecal incontinence are 
advisable to tailor patients’ management. 
Chiarioni G, Palsson OS, Asteria CR, Whitehead WE. Neuromod-
ulation for fecal incontinence: An effective surgical intervention. 




Fecal incontinence (FI) is defined as the accidental loss 
of  solid or liquid stools and is a common disabling condi-
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because of  fear and embarrassment. In a recent study 
of  > 1500 primary care patients, FI was self-reported by 
36.2% of  patients, but only 2.7% of  them had a medical 
diagnosis of  FI[1]. FI has a significant impact on quality 
of  life (QOL) and health expenditure and may facilitate 
the placement of  older patients in nursing home facili-
ties[2]. Therefore, increased medical screening of  FI is 
needed because both conservative and interventional 
treatments are available. Biofeedback therapy to increase 
rectal awareness of  stools and ameliorate anal sphinc-
ter response improved continence in about two-thirds 
of  patients in open and randomized controlled trials 
(RCTs)[3,4]. However, patients with severe impairment of  
rectal sensation and/or previous anal trauma do poorly 
with biofeedback, and alternative options are desirable in 
selected patients[5]. In the past a number of  surgical pro-
cedures has been proposed to treat FI. Major drawbacks 
were the small sample sizes and potential worsening of  
incontinence[6]. Sacral nerve electrostimulation, later also 
called neuromodulation (NRM), was first applied in 1995 
by Matzel et al[7] with encouraging results in a small group 
of  patients with FI without evidence of  anal sphincter 
defects. The technique was attractive because of  its lim-
ited side effects and for being minimally invasive. Since 
then, the effectiveness of  NRM in improving FI has 
been proven in a number of  studies, although its mecha-
nism of  action remains ill defined[8]. However, physicians 
involved in the treatment of  disordered anal continence 
should consider NRM among potential treatment op-
tions, and this review is intended to be a primer for the 
non-surgical community.
Search methods
Search terms were fecal incontinence OR anal inconti-
nence and sacral nerve stimulation OR neuromodulation. 
These searches were limited to human subjects, adults, 
and studies published in full in the English language be-
tween January 1995 and December 2012. Case reports, 
preliminary studies, and small sample series investigating 
< 15 patients were not considered. Databases searched 
were PubMed, Web of  Science, Cochrane Reviews, and 
Embase. The bibliographies of  identified studies were 
also searched for additional references. To address NRM 
effectiveness, special consideration was given to RCTs 
and adequately powered prospective trials. 
TECHNIQUE, SAFETY AND MECHANISM 
OF ACTION OF NRM
Technique
NRM is a minimally invasive surgical intervention con-
sisting of: (1) a testing evaluation interval; and (2) a 
second stage with permanent stimulator implantation, 
provided the testing interval results are clinically suc-
cessful. The first stage, also termed percutaneous nerve 
evaluation (PNE), is of  most relevance to determine the 
feasibility of  electrode implantation into the sacral foram-
ina, and to demonstrate clinical benefits worth pursuing 
with permanent NRM[9]. Two technical options are avail-
able for PNE: a temporary, percutaneously placed, uni-
polar stimulation lead to be later removed, or the surgical 
placement of  a quadripolar lead next to a target nerve[9]. 
Both types of  leads are then connected to an external 
pulse generator to be substituted by a permanent pulse 
generator implanted subcutaneously in case of  positive 
outcome. The permanent implant sized a quarter dollar 
or 2 euro coin (diameter 24.26 mm, thickness 1.75 mm) is 
commonly placed in the gluteal area and can be managed 
by a small handheld device[9]. A small retrospective study 
evaluated outcome and complications of  the two PNE 
techniques[10]. No difference in outcome was shown, but 
the infection rate was slightly higher in patients undergo-
ing surgical placement. 
Safety
The commonest adverse events are implant site pain and 
paresthesia, which is seen in up to 28% of  patients in 
some large series with careful reporting about safety[11,12]. 
Pain is usually managed conservatively and explant of  the 
device is rarely needed. However, a recent meta-analysis 
concluded that incidence of  implant site pain may be as 
low as 6%[8]. The most serious complication is infection 
at the implant site, which was seen in up to 10.8% in the 
largest series of  > 100 patients[11,12]. The control of  site 
infection may require device explant in approximately 
half  of  those affected[12]. The meta-analysis by Tan et 
al[8] supports diverse evidence indicating that the typical 
infection rate is 3%, with the proportion requiring the 
device to be removed for refractory infection being about 
3% of  those infected. Additional side effects reported in 
< 8% of  patients are urinary incontinence, diarrhea, and 
extremity pain, which always resolve spontaneously or 
are effectively managed by medication[8]. In older series, 
broken or displaced electrodes occurred in about 4% 
of  cases[8], and sometimes required device explantation. 
However, this problem is becoming less frequent since 
the electrodes were redesigned. Battery replacement is 
usually required after a median of  7 years[13]. 
Mechanism of action
In 1999, Vaizey et al[14] first reported the effect of  NRM 
on anorectal physiology measured by 24-h solid state 
catheter manometry in a small group of  10 patients with 
FI. Resting anal pressure did not change significantly 
and some evidence of  modification of  rectal sensitiv-
ity and tone was observed. The authors speculated that 
NRM worked via complex neuromodulation of  sacral 
reflexes to regulate rectal sensitivity and anorectal motil-
ity[14]. Since then, several studies focused on modifica-
tions of  anorectal physiology associated with NRM in FI, 
with conflicting results. In their meta-analysis, Tan et al[8] 
concluded that NRM is associated with improvement in 
anal canal pressure at rest and with voluntary squeezing, 
and a decrease in the maximum tolerable rectal volume. 
However, subsequent studies had inconsistent results, 
with RCTs and long-term studies failing to show a rel-
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evant influence of  NRM on anal pressure[15,16]. When 
there are significant improvements in anal canal pressure, 
the size of  the effect is small and the final resting and 
squeeze pressures appear to be below the normal range 
for healthy controls[8]. This is not commensurate with 
the large clinical effects seen for FI and suggests that the 
mechanism by which NRM improves continence is not 
primarily an improvement in anal canal pressure. This 
issue was addressed in a recent review by Gourcerol et 
al[17], which specifically focused on defining the potential 
mechanism of  action of  NRM. The authors speculated 
on three potential mechanisms: (1) somatovisceral reflex; 
(2) modulation of  the perception of  afferent informa-
tion; and (3) increase in external anal sphincter activity[17]. 
However, no definitive evidence could be found to sup-
port any of  these and a multifactorial component was 
further speculated to justify the efficacy of  NRM. The 
authors concluded that NRM is effective almost certainly 
via modulation of  spinal and/or supraspinal afferent in-
puts, but many gaps remain in the understanding of  the 
mechanism of  action of  NRM[17]. 
EFFECTIVENESS
RCTs
After the early report of  Matzel et al[7], a number of  trials 
were developed to evaluate the efficacy of  NRM in FI[7,8]. 
A major drawback to assessing this literature is the huge 
variance in inclusion and outcome criteria and follow-
up intervals[8]. Additional limitations are small sample 
size (often < 20 patients) and lack of  adequate control 
groups[8]. However, the majority of  uncontrolled trials 
reported a favorable outcome in more than two-thirds 
of  patients with limited side-effects. Researchers were 
unable to identify any clinical and/or functional variable 
that could predict outcome[8]. In earlier reports, patients 
were selected on findings of  either no or marginal evi-
dence of  anal sphincter defects. However, this limitation 
was later dropped because of  the unclear definition of  
the mechanism of  action of  the treatment[8]. In 2005, 
Leroi et al[18] reported on the first randomized, controlled, 
double blind, multicenter study testing the efficacy of  
NRM in FI and/or severe urgency of  any etiology. Pa-
tients with an ultrasound diagnosis of  sphincter defect 
were included, provided the defect was not considered 
to be the main determinant of  incontinence[18]. After 
implantation, 27 of  34 patients with FI were randomized 
in a double-blind crossover manner to NRM active treat-
ment (electrostimulator ON) vs placebo (electrostimula-
tor OFF) for a 1-mo period with the device in situ. A 
final interval of  3 mo was also included in the evaluation 
with patients still blinded, potentially choosing either 
the ON or the OFF modality[18]. Twenty-four patients 
completed the trial, making the sample underpowered. 
However, patients reported a significant improvement 
in both symptoms and QOL scores, and anal physiology 
when in active treatment compared to placebo, providing 
evidence that a placebo effect was not the main determi-
nant of  NRM outcome[18]. However, until recently, NRM 
was not compared to conservative management (diet, 
lifestyle modification, constipating drugs, and biofeed-
back), which is cheaper, commonly available, and often 
associated with benefits in at least 50% of  patients with 
FI[3]. Tjandra et al[15] randomized 120 patients with FI to 
either supervised optimal medical therapy or NRM. Con-
servative treatment included bulking agents, pelvic floor 
exercises, or lifestyle and dietary manipulations, but it did 
not include biofeedback[15]. NRM was significantly more 
effective in improving frequency of  incontinence with 25 
patients regaining perfect continence[15]. Cleveland Clinic 
Continence Score and QOL score were both significantly 
improved as well[15]. 
Open label trials and meta-analysis
In a recent prospective, open label, multicenter trial, 
Wexner et al[11] confirmed the effectiveness of  NRM in 
improving FI in a large sample of  120 patients with 112 
of  them undergoing permanent implantation. The vast 
majority of  patients (83%) reported significant improve-
ment of  FI according to the outcome measurement se-
lected, including 41% gaining complete anal continence, 
after a mean follow-up of  28 mo[11]. FI is a chronic dis-
order, therefore, Mellgren et al[12] reported on the same 
cohort after a mean follow-up of  3.1 years (range: 0.2-6.1 
years) with at least a partial data set available in 64% of  
the patients. A significant decrease in episodes of  incon-
tinence was still reported by 86% of  available patients 
with 41% regaining continence. A stable improvement in 
QOL score was also reported by patients[12]. To deepen 
the analysis, a carried forward observation at 3 years was 
performed showing a 78% success rate. However, the 
success rate dropped to 59% at 3 years when considering 
all missing data as failures[12]. Historically, anal sphincter 
disruption has been considered a contraindication to 
perform NRM, which was not even considered in the 
presence of  a relevant morphological alteration[7-9]. How-
ever, Chan et al[19] provided sound evidence against this 
assumption in a comparative cohort study. The effective-
ness of  NRM in improving FI and QOL at 1 year was 
not significantly different in 21 patients with a disrupted 
external anal sphincter (81% persisting after previous 
sphincter repair) when compared to the outcome of  32 
patients with FI and an intact anal sphincter[19]. These 
data were confirmed by an RCT comparing NRM with 
conservative treatment in which many patients with de-
fects in both the internal and external sphincters were in-
cluded, showing that NRM was equally effective in those 
with or without sphincter disruption[15]. The therapeutic 
potential of  NRM compared to conservative treatment in 
FI has also been reported in several, mostly small studies 
including patients with distinct pathological conditions, 
including rectal resection and pelvic irradiation[8,20,21]. In 
these distinct conditions dealt with in the following sec-
tion, FI response rates may be lower, with about 50% 
of  patients responding to temporary stimulation[20,21]. A 
recent meta-analysis by Tan et al[8] reported on a total of  
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fit of  NRM in double incontinence[9]. Caremel et al[29] first 
reported on clinical questionnaires sent to 57 patients 
with double incontinence treated by permanent implan-
tation, with FI as the main indication for NRM in 60% 
of  them. About two-thirds of  patients responded, with 
49% reporting an improvement in both fecal and urinary 
incontinence. Patients implanted for urinary incontinence 
as the main indication were more likely to report full 
amelioration of  both types of  incontinence[29]. Recently, 
Faucheron et al[30] reported a single-center study of  57 pa-
tients (54 women) who underwent PNE and permanent 
implantation for double incontinence of  multiple etiol-
ogy, with a median follow-up of  62.8 mo. Improvement 
in both fecal and urinary incontinence was evaluated by 
dedicated scores, with about 50% of  patients reporting 
amelioration of  both symptoms[30]. Surprisingly, bladder-
related clinical improvement scored slightly lower than 
bowel-related improvement. Re-intervention rate (29%) 
and complication rate (12%) were both relatively high[30]. 
Rectal resection for cancer and pelvic radiotherapy are 
conditions commonly associated with secondary severe 
alterations in bowel compliance[3]. Incontinence is pre-
dominant at night and mostly deemed incurable[2,3]. Two 
European groups investigated the efficacy of  NRM in 
these hard-to-treat conditions in small samples. Both 
studies reported PNE to be effective in improving conti-
nence in approximately half  of  those treated, but the ef-
ficacy of  permanent implantation was not reported[20,21]. 
Atrophy of  the anal sphincter is an additional hard-to-
treat FI disease for which NRM has been associated with 
clinical benefit in open trials. Santoro et al[31] have report-
ed a single-center study of  28 patients with magnetic-
resonance-imaging-documented external anal sphincter 
atrophy of  different severity undergoing permanent 
implantation for FI. A significant improvement in both 
FI and QOL scores was reported regardless of  severity 
of  sphincter atrophy[31]. This study provided indirect evi-
dence of  improvement in anal sphincter function as the 
mechanism of  action of  NRM[31]. Finally, a few studies 
have evaluated the efficacy of  NRM for loss of  normal 
bowel function due to nerve injury, neurological disease, 
or congenital defects of  the nervous system - so-called 
neurogenic bowel. Holzer et al[32] assessed clinical out-
come in a cohort of  29 patients undergoing permanent 
implantation for FI of  mixed neurological etiology, in-
cluding diabetes. The authors claimed that most patients 
were symptomatically improved, but outcome parameters 
were ill defined[32]. Recently, an Italian group reported on 
the efficacy of  NRM in improving symptoms of  pelvic 
floor dysfunction in 23 patients with incomplete spinal 
cord damage[33]. A significant improvement in FI was 
found in the majority of  patients, but the grouping of  
patients with both constipation and FI made it hard to 
interpret the results[33].
COST
The cost of  NRM is high when compared to conserva-
tive medical management, pelvic floor exercises and 
biofeedback therapy. Actual cost of  NRM varies widely 
among countries as well as health insurance conditions. 
However, studies from three different countries have 
concluded that NRM is cost-effective when offset by the 
quality-adjusted life-years gained, and that it is likely to be 
reimbursed by government health programs[22,24,34,35]. 
CONCLUSION
In conclusion, NRM is effective for FI of  diverse etiol-
ogy. Encouraging results have also been reported for 
FI therapy in distinct and rare conditions, but RCTs are 
lacking and no firm conclusion can be actually drawn. 
NRM is reported to have long-term benefit in more than 
two-thirds of  patients with FI undergoing permanent 
implantation, by some as-yet-unknown mechanism. 
However, when analyzed by ITT analysis, the median 
responder rate drops to 59% of  those treated. NRM is 
a minimally invasive procedure. The most common seri-
ous adverse event is infection at the site of  implantation, 
which occurs in about 3% of  cases and requires device 
explantation in about 3% of  all patients receiving perma-
nent implants. Cost of  treatment is high relative to that 
of  conservative treatment and biofeedback but there are 
studies from different countries suggesting that NRM is 
cost-effective when offset by gains in quality-adjusted life 
years. However, RCTs comparing NRM to biofeedback 
therapy for FI are required to resolve this issue.
REFERENCES
1 Dunivan GC, Heymen S, Palsson OS, von Korff M, Turner 
MJ, Melville JL, Whitehead WE. Fecal incontinence in pri-
mary care: prevalence, diagnosis, and health care utilization. 
Am J Obstet Gynecol 2010; 202: 493.e1-493.e6 [PMID: 20223447 
DOI: 10.1016/j.ajog.2010.01.018]
2 Miner PB. Economic and personal impact of fecal and uri-
nary incontinence. Gastroenterology 2004; 126: S8-13 [PMID: 
14978633 DOI: 10.1053/j.gastro.2003.10.056]
3 Chiarioni G, Ferri B, Morelli A, Iantorno G, Bassotti G. Bio-
feedback treatment of fecal incontinence: where are we, and 
where are we going? World J Gastroenterol 2005; 11: 4771-4775 
[PMID: 16097042]
4 Heymen S, Scarlett Y, Jones K, Ringel Y, Drossman D, 
Whitehead WE. Randomized controlled trial shows biofeed-
back to be superior to pelvic floor exercises for fecal inconti-
nence. Dis Colon Rectum 2009; 52: 1730-1737 [PMID: 19966605 
DOI: 10.1007/DCR.0b013e3181b55455]
5 Chiarioni G, Bassotti G, Stanganini S, Vantini I, White-
head WE. Sensory retraining is key to biofeedback 
therapy for formed stool fecal incontinence. Am J Gastro-
enterol 2002; 97: 109-117 [PMID: 11808933 DOI: 10.1111/
j.1572-0241.2002.05429.x]
6 Michot F, Costaglioli B, Leroi AM, Denis P. Artificial anal 
sphincter in severe fecal incontinence: outcome of pro-
spective experience with 37 patients in one institution. 
Ann Surg 2003; 237: 52-56 [PMID: 12496530 DOI: 10.1007/
DCR.0b013e3181e19d68]
7 Matzel KE, Stadelmaier U, Hohenfellner M, Gall FP. Electri-
cal stimulation of sacral spinal nerves for treatment of faecal 
incontinence. Lancet 1995; 346: 1124-1127 [PMID: 7475602 
DOI: 10.1016/S0140-6736(95)91799-3]
8 Tan E, Ngo NT, Darzi A, Shenouda M, Tekkis PP. Meta-
Chiarioni G et al . Neuromodulation for fecal incontinence
7054 November 7, 2013|Volume 19|Issue 41|WJG|www.wjgnet.com
analysis: sacral nerve stimulation versus conservative thera-
py in the treatment of faecal incontinence. Int J Colorectal Dis 
2011; 26: 275-294 [PMID: 21279370 DOI: 10.1007/s00384-010-
1119-y]
9 Tjandra JJ, Lim JF, Matzel K. Sacral nerve stimulation: 
an emerging treatment for faecal incontinence. ANZ J 
Surg 2004; 74: 1098-1106 [PMID: 15574154 DOI: 10.1111/
j.1445-1433.2004.03259.x]
10 Dudding TC, Parés D, Vaizey CJ, Kamm MA. Compari-
son of clinical outcome between open and percutaneous 
lead insertion for permanent sacral nerve neurostimula-
tion for the treatment of fecal incontinence. Dis Colon 
Rectum 2009; 52: 463-468 [PMID: 19333047 DOI: 10.1007/
DCR.0b013e318197e31f]
11 Wexner SD, Coller JA, Devroede G, Hull T, McCallum R, 
Chan M, Ayscue JM, Shobeiri AS, Margolin D, England M, 
Kaufman H, Snape WJ, Mutlu E, Chua H, Pettit P, Nagle D, 
Madoff RD, Lerew DR, Mellgren A. Sacral nerve stimula-
tion for fecal incontinence: results of a 120-patient prospec-
tive multicenter study. Ann Surg 2010; 251: 441-449 [PMID: 
20160636 DOI: 10.1097/SLA.0b013e3181cf8ed0]
12 Mellgren A, Wexner SD, Coller JA, Devroede G, Lerew 
DR, Madoff RD, Hull T. Long-term efficacy and safety of 
sacral nerve stimulation for fecal incontinence. Dis Colon 
Rectum 2011; 54: 1065-1075 [PMID: 21825885 DOI: 10.1097/
DCR.0b013e31822155e9]
13 Hollingshead JR, Dudding TC, Vaizey CJ. Sacral nerve 
stimulation for faecal incontinence: results from a single cen-
tre over a 10-year period. Colorectal Dis 2011; 13: 1030-1034 
[PMID: 20718837 DOI: 10.1111/j.1463-1318.2010.02383.x]
14 Vaizey CJ, Kamm MA, Turner IC, Nicholls RJ, Woloszko 
J. Effects of short term sacral nerve stimulation on anal and 
rectal function in patients with anal incontinence. Gut 1999; 
44: 407-412 [PMID: 10026329 DOI: 10.1136/gut.44.3.407]
15 Tjandra JJ, Chan MK, Yeh CH, Murray-Green C. Sacral 
nerve stimulation is more effective than optimal medical 
therapy for severe fecal incontinence: a randomized, con-
trolled study. Dis Colon Rectum 2008; 51: 494-502 [PMID: 
18278532 DOI: 10.1007/s10350-007-9103-5]
16 Michelsen HB, Thompson-Fawcett M, Lundby L, Krogh 
K, Laurberg S, Buntzen S. Six years of experience with 
sacral nerve stimulation for fecal incontinence. Dis Colon 
Rectum 2010; 53: 414-421 [PMID: 20305440 DOI: 10.1007/
DCR.0b013e3181ca7dc2]
17 Gourcerol G, Vitton V, Leroi AM, Michot F, Abysique A, 
Bouvier M. How sacral nerve stimulation works in patients 
with faecal incontinence. Colorectal Dis 2011; 13: e203-e211 
[PMID: 21689312 DOI: 10.1111/j.1463-1318.2011.02623.x]
18 Leroi AM, Parc Y, Lehur PA, Mion F, Barth X, Rullier E, 
Bresler L, Portier G, Michot F. Efficacy of sacral nerve stimu-
lation for fecal incontinence: results of a multicenter double-
blind crossover study. Ann Surg 2005; 242: 662-669 [PMID: 
16244539 DOI: 10.1097/01.sla.0000186281.09475.db]
19 Chan MK, Tjandra JJ. Sacral nerve stimulation for fecal 
incontinence: external anal sphincter defect vs. intact anal 
sphincter. Dis Colon Rectum 2008; 51: 1015-124; discussion 
1015-124; [PMID: 18484136 DOI: 10.1007/s10350-008-9326-0]
20 Maeda Y, Høyer M, Lundby L, Buntzen S, Laurberg S. Tem-
porary sacral nerve stimulation for faecal incontinence fol-
lowing pelvic radiotherapy. Radiother Oncol 2010; 97: 108-112 
[PMID: 20570003 DOI: 10.1016/j.radonc.2010.12.004]
21 de Miguel M, Oteiza F, Ciga MA, Armendáriz P, Marzo J, 
Ortiz H. Sacral nerve stimulation for the treatment of fae-
cal incontinence following low anterior resection for rectal 
cancer. Colorectal Dis 2011; 13: 72-77 [PMID: 19843119 DOI: 
10.1111/j.1463-1318.2009.02066.x]
22 Dudding TC, Meng Lee E, Faiz O, Parés D, Vaizey CJ, 
McGuire A, Kamm MA. Economic evaluation of sacral 
nerve stimulation for faecal incontinence. Br J Surg 2008; 95: 
1155-1163 [PMID: 18581439 DOI: 10.1002/bjs.6237]
23 Altomare DF, Ratto C, Ganio E, Lolli P, Masin A, Villani RD. 
Long-term outcome of sacral nerve stimulation for fecal in-
continence. Dis Colon Rectum 2009; 52: 11-17 [PMID: 19273950 
DOI: 10.1007/DCR.0b013e3181974444]
24 Muñoz-Duyos A, Navarro-Luna A, Brosa M, Pando JA, Sit-
ges-Serra A, Marco-Molina C. Clinical and cost effectiveness 
of sacral nerve stimulation for faecal incontinence. Br J Surg 
2008; 95: 1037-1043 [PMID: 18574847 DOI: 10.1002/bjs.6140]
25 Duelund-Jakobsen J, van Wunnik B, Buntzen S, Lundby L, 
Baeten C, Laurberg S. Functional results and patient satisfac-
tion with sacral nerve stimulation for idiopathic faecal in-
continence. Colorectal Dis 2012; 14: 753-759 [PMID: 21883814 
DOI: 10.1111/j.1463-1318.2011.02800.x]
26 Matzel KE, Lux P, Heuer S, Besendörfer M, Zhang W. Sacral 
nerve stimulation for faecal incontinence: long-term out-
come. Colorectal Dis 2009; 11: 636-641 [PMID: 18727721 DOI: 
10.1111/j.1463-1318.2008.01673.x]
27 Uludağ O, Melenhorst J, Koch SM, van Gemert WG, Dejong 
CH, Baeten CG. Sacral neuromodulation: long-term out-
come and quality of life in patients with faecal incontinence. 
Colorectal Dis 2011; 13: 1162-1166 [PMID: 20955512 DOI: 
10.1111/j.1463-1318.2010.02447.x]
28 Michelsen HB, Krogh K, Buntzen S, Laurberg S. A prospec-
tive, randomized study: switch off the sacral nerve stimu-
lator during the night? Dis Colon Rectum 2008; 51: 538-540 
[PMID: 18299927 DOI: 10.1007/s10350-008-9219-2]
29 Caremel R, Damon H, Ruffion A, Chartier-Kastler E, 
Gourcerol G, Michot F, Menard JF, Grise P, Leroi AM. Can 
sacral neuromodulation improve minor incontinence symp-
toms in doubly incontinent patients successfully treated 
for major incontinence symptoms? Urology 2012; 79: 80-85 
[PMID: 22099864 DOI: 10.1016/j.urology.2011.06.013]
30 Faucheron JL, Chodez M, Boillot B. Neuromodulation for 
fecal and urinary incontinence: functional results in 57 
consecutive patients from a single institution. Dis Colon 
Rectum 2012; 55: 1278-1283 [PMID: 23135587 DOI: 10.1097/
DCR.0b013e31826c7789]
31 Santoro GA, Infantino A, Cancian L, Battistella G, Di Falco G. 
Sacral nerve stimulation for fecal incontinence related to ex-
ternal sphincter atrophy. Dis Colon Rectum 2012; 55: 797-805 
[PMID: 22706133 DOI: 10.1097/DCR.0b013e3182538f14]
32 Holzer B, Rosen HR, Novi G, Ausch C, Hölbling N, Schies-
sel R. Sacral nerve stimulation for neurogenic faecal incon-
tinence. Br J Surg 2007; 94: 749-753 [PMID: 17410558 DOI: 
10.1002/bjs.5499]
33 Lombardi G, Del Popolo G, Cecconi F, Surrenti E, Mac-
chiarella A. Clinical outcome of sacral neuromodulation 
in incomplete spinal cord-injured patients suffering from 
neurogenic bowel dysfunctions. Spinal Cord 2010; 48: 154-159 
[PMID: 19668257 DOI: 10.1038/sc.2009.101]
34 Ratto C, Litta F, Parello A, Donisi L, Doglietto GB. Sacral 
nerve stimulation is a valid approach in fecal incontinence 
due to sphincter lesions when compared to sphincter repair. 
Dis Colon Rectum 2010; 53: 264-272 [PMID: 20173471 DOI: 
10.1007/DCR.0b013e3181c7642c]
35 Indinnimeo M, Ratto C, Moschella CM, Fiore A, Brosa M, 
Giardina S. Sacral neuromodulation for the treatment of 
fecal incontinence: analysis of cost-effectiveness. Dis Colon 
Rectum 2010; 53: 1661-1669 [PMID: 21178862 DOI: 10.1007/
DCR.0b013e3181f46309]
P- Reviewer: Santoro GA    S- Editor: Song XX    L- Editor: Kerr C 
E- Editor: Zhang DN
Chiarioni G et al . Neuromodulation for fecal incontinence
© 2013 Baishideng Publishing Group Co., Limited. All rights reserved.
Published by Baishideng Publishing Group Co., Limited
Flat C, 23/F., Lucky Plaza, 





I S S N  1 0  0 7  -   9  3 2  7
9    7 7 1 0  07   9 3 2 0 45
4  1
